Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors

Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors

Lung cancer remains the first cause of cancer-related death despite many therapeutic innovations, including immune checkpoint inhibitors (ICI). ICI are now well used in daily practice at late metastatic stages and locally advanced stages after a chemo-radiation. ICI are also emerging in the peri-ope...

Full description

Bibliographic Details
Main Authors: Julien Ancel, Valérian Dormoy, Béatrice Nawrocki Raby, Véronique Dalstein, Anne Durlach, Maxime Dewolf, Christine Gilles, Myriam Polette, Gaëtan Deslée
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-05-01
Series:Frontiers in Immunology
Subjects:
liquid biopsy
soluble biomarkers
immunotherapy
non-small cell lung cancer (NSCLC)
neutrophil lymphocyte ratio (NLR)
circulating tumor (ctDNA)
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1171649/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1171649/full

Similar Items